Literature DB >> 2321777

Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.

G C Allen1, H Rosenberg, J E Fletcher.   

Abstract

Anesthetic management and outcome were examined in patients with negative in vitro contracture tests for malignant hyperthermia (MH). Contracture testing was performed in a standardized fashion using 3% halothane alone and incremental doses of caffeine alone. Medical records were examined for 54 anesthetic exposures in 42 MH(-) patients who had received anesthesia since their MH testing. Sixteen patients received anesthesia with known MH triggering agents on 23 occasions, all without incident. In six MH(-) patients with previous masseter muscle rigidity, no adverse reactions occurred in response to volatile anesthetic agents. Succinylcholine was avoided in these patients. Eleven MH(-) patients were managed as if MH-susceptible, although it was known that these patients had tested MH(-). Two of these patients also receive prophylactic iv dantrolene. These results suggest that "triggering" anesthetic agents may be safely administered to patients who test MH(-) by in vitro contracture testing. However, until the anesthetic experience of larger numbers of MH(-) patients is known, these results should be interpreted cautiously.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2321777     DOI: 10.1097/00000542-199004000-00007

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  3 in total

Review 1.  Malignant hyperthermia.

Authors:  R Ben Abraham; P Adnet; V Glauber; A Perel
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

2.  Diagnosis of malignant hyperthermia: a comparison of the in vitro contracture test with the molecular genetic diagnosis in a large pedigree.

Authors:  J M Healy; K A Quane; K E Keating; M Lehane; J J Heffron; T V McCarthy
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

3.  Anterior mediastinal mass in a patient susceptible to malignant hyperthermia.

Authors:  G C Allen; L J Byford; F M Shamji
Journal:  Can J Anaesth       Date:  1993-01       Impact factor: 5.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.